Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21764887.
- Also identified by DOI 10.1158/1078-0432.CCR-10-2051.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The recent incremental advances made in the treatment of metastatic breast cancer have elicited potential for survival extension in this treatable, yet incurable, population of breast cancer patients. Clinicians have focused on targeted therapies, which aim at signaling receptors such as the human epidermal receptor superfamily, the estrogen receptor, VEGF, the insulin-like growth factor receptor, the hepatocyte growth factor receptor (cMET), phosphoinositide 3-kinase, mTOR, and many others.
Medical subject headings
- Antineoplastic Agents, Hormonal
- Antineoplastic Combined Chemotherapy Protocols
- Breast Neoplasms
- Molecular Targeted Therapy
- Erb-b2 Receptor Tyrosine Kinases
- Receptors, Estrogen